Abstract 621P
Background
Early detection of primary liver cancer (PLC) in patients with liver cirrhosis (LC) or chronic hepatitis virus infection (CHVI) improves survival. The urgent need is convenient and affordable tools with high sensitivity to facilitate timely diagnosis.
Methods
Tissue and plasma samples from 159 healthy individuals and 89 PLC, LC, or CHVI patients were sequenced by a targeted methylation panel (∼70,000 CpGs) to identify candidate methylated DNA markers (MDMs). In phase I, the performance of each selected MDMs was validated in 175 plasma samples (PLC, n=101; LC/CHVI, n=74) by CO-methylation aMplification rEal-Time PCR (COMET) assay. A logistic model was then trained and validated in phase II with 310 plasma samples (hepatocellular carcinoma [HCC], n=212; combined hepatocellular-cholangiocarcinoma [cHCC-CC], n=12; CHVI, n=106; training vs. validation, 2:1).
Results
The 11 selected MDMs with top performance consistently showed significant differences in tissue samples between PLC and LC/CHVI, as well as in plasma samples between PLC and LC/CHVI (P<0.05). In phase I, 8 of the above 11 MDMs with an area under the curve (AUC) over 0.80 to differentiate PLC and LC/CHVI were selected for further investigation. In phase II, the MDM-based model achieved sensitivity of 87.2% (95% confidence interval [CI], 80.8%–92.4%) and 88.0% (78.4%–94.4%), at respective specificity of 97.1% (90.1%–99.7%) and 100% (90.3%–100%) in the training and validation sets. In the validation set, sensitivity in patients with BCLC stage 0, diameter<3 cm, AFP-negative and PIVKA-II-negative was 90.0% (55.5%–99.7%), 88.9% (65.3%–98.6%), 80.6% (64.0%–91.8%), and 81.3% (54.4%–96.0%), respectively. Additionally, our model detected 19 of 24 (79.3%, 57.8%–92.9%) intrahepatic cholangiocarcinoma. Combining AFP and PIVKA-II, the model achieved higher sensitivity of 93.3% (85.1%–97.8%) and specificity of 100.0% (90.3%–100%).
Conclusions
COMET featuring low cost and high accuracy exhibits preferable potential for PLC detection in patients with LC or CHVI. Further validation in a prospective cohort is warranted.
Clinical trial identification
NCT05996666, release date 08/10/2023.
Editorial acknowledgement
Legal entity responsible for the study
Tian Yang.
Funding
National Natural Science Foundation of China (No: 81972726 and 82273074), Dawn Project Foundation of Shanghai (No: 21SG36), Shanghai Health Academic Leader Program (No. 2022XD001).
Disclosure
X. Zhu, L. Zhang, Q. You, J. Xu, Y. Xu, H. Lu, B. Li, G. Wang, S. Cai: Financial Interests, Personal, Full or part-time Employment: Burning Rock Biotech. All other authors have declared no conflicts of interest.
Resources from the same session
62P - Combination of chemotherapy with endocrinal therapy as upfront treatment of metastatic breast cancer in hormone receptor- positive, HER2 -negative disease: A phase II randomised clinical trial
Presenter: Mariam Saleh
Session: Poster Display
Resources:
Abstract
63P - Efficacy and safety of eribulin plus carboplatin combination for HER2-negative metastatic breast cancer
Presenter: Mengqian Ni
Session: Poster Display
Resources:
Abstract
64P - Unmet needs following metastatic breast cancer in a middle-income Asian country
Presenter: Nirmala Bhoo-Pathy
Session: Poster Display
Resources:
Abstract
66P - Utidelone-based therapy in metastatic solid tumors after failure of standard therapies: A prospective, multicenter, single-arm trial
Presenter: Jianjun Zhang
Session: Poster Display
Resources:
Abstract
67P - Efficacy and safety of trastuzumab biosimilar in HER2+ve metastatic breast cancer: A multicenter phase III study
Presenter: krishna Mohan
Session: Poster Display
Resources:
Abstract
68P - Neratinib in combination with fulvestrant and or palbociclib can overcome endocrine resistance in HER2-low/ ER+ breast cancer
Presenter: Maryam Arshad
Session: Poster Display
Resources:
Abstract
69P - A multicenter, retrospective, real-world study of inetetamab combined with pyrotinib and vinorelbine as treatment for HER2-positive metastatic breast cancer
Presenter: Nan Jin
Session: Poster Display
Resources:
Abstract
70P - Overall survival of eribulin, trastuzumab, and pertuzumab as first-line therapy for patients with HER2-positive metastatic breast cancer: A phase II, single-arm clinical trial
Presenter: Kenichi Inoue
Session: Poster Display
Resources:
Abstract
71P - Efficacy and safety of disitamab vedotin after trastuzumab for HER2 -positive breast cancer: A real-world data of retrospective study
Presenter: Chao Li
Session: Poster Display
Resources:
Abstract
72P - Real-world data on the efficacy of T-DM1 biosimilar for the treatment of HER2-positive metastatic breast cancer patients: Outcomes from a single center retrospective study in India
Presenter: Kaushal Patel
Session: Poster Display
Resources:
Abstract